Innovating Works

OCUPHARM

Desconocido
CRYSTAL3: Commercial Research Opportunity for Cysteinyl Leukotriene Signalling in Ocular CNS Dysfunction... OCUPHARM DIAGNOSTICS SL participó en un H2020: H2020-MSCA-RISE-2020 Cysteinyl leukotrienes (CysLTs) are potent lipid mediators of inflammation. CysLT1 and 2 receptors are widely expressed e.g. lungs, colorect...
2020-10-02 - 2024-12-31 | Financiado
ORBITAL: Ocular Research By Integrated Training And Learning Diseases of the posterior segment of the eye are increasing considerably, partly due to an ageing population (almost 20% of the population o...
2019-04-09 - 2024-02-29 | Financiado
3D NEONET: Drug Discovery and Delivery NEtwork for ONcology and Eye Therapeutics OCUPHARM DIAGNOSTICS SL participó en un H2020: H2020-MSCA-RISE-2016 Severe ocular disorders are affecting the lives of more than 100Mill people world-wide and at least 25% of the population above 70 years of...
2016-11-08 - 2022-06-30 | Financiado
DryEye: Validation of a Novel Diagnostic Biomarker for Dry Eye Syndrome based in nucleotides detection OCUPHARM DIAGNOSTICS SL tramitó un H2020: H2020-SMEInst-2014-2015 Scientists of our company invented a method for diagnosing and monitoring the effectiveness of dry-eye syndrome treatment. The invention is...
2015-05-04 - 2016-01-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.